UHPLC-MS/MS for plasma lamotrigineanalysis and comparison with a homogenousenzyme immunoassay: supplementary data

Aims: To develop and validate a UHPLC-MS/MS method for lamotrigine (LTG) analysis in human plasma
and evaluate its agreement with a homogenous enzyme immunoassay (HEIA). Materials & methods: The
UHPLC-MS/MS method was developed and validated according to the USFDA/EMA guidelines. A Bland–
Altman plot was used to evaluate the agreement between UHPLC-MS/MS and HEIA. Results: Samples were
pretreated with one-step protein precipitation and separated in 2.6 min. The intra- and inter-day bias
and imprecisions were -15.8 to 15.0% and less than 11.17%, respectively. The recovery and matrix factor
were 98.30 to 111.97%. The mean overestimation of UHPLC-MS/MS compared with HEIA was 21.57%.
Conclusion: A rapid, sensitive and robust UHPLC-MS/MS method for plasma LTG analysis was developed
and validated and was a 21.57% overestimation compared with HEIA.